NASDAQ:ANIK - Anika Therapeutics Stock Price, News, & Analysis

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Anika Therapeutics Inc (NASDAQ:ANIK) released its quarterly earnings data on Thursday, May, 2nd. The biotechnology company reported $0.31 EPS for the quarter, beating the Zacks' consensus estimate of $0.21 by $0.10. The biotechnology company earned $24.72 million during the quarter, compared to analysts' expectations of $22.06 million. Anika Therapeutics had a net margin of 27.44% and a return on equity of 11.57%. The firm's quarterly revenue was up 16.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.46) EPS. View Anika Therapeutics' Earnings History.

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for Anika Therapeutics.

4 equities research analysts have issued 12-month price targets for Anika Therapeutics' stock. Their forecasts range from $35.00 to $44.00. On average, they anticipate Anika Therapeutics' stock price to reach $38.6667 in the next twelve months. This suggests that the stock has a possible downside of 4.5%. View Analyst Price Targets for Anika Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics.

News stories about ANIK stock have trended somewhat negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Anika Therapeutics earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Anika Therapeutics.

Anika Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 3,145,000 shares, an increase of 19.7% from the April 15th total of 2,626,900 shares. Based on an average daily volume of 208,600 shares, the days-to-cover ratio is presently 15.1 days. Currently, 23.0% of the shares of the stock are short sold. View Anika Therapeutics' Current Options Chain.

Some companies that are related to Anika Therapeutics include Nevro (NVRO), Irhythm Technologies (IRTC), Atrion (ATRI), Shockwave Medical (SWAV), Mazor Robotics (MZOR), Silk Road Medical (SILK), Cardiovascular Systems (CSII), AtriCure (ATRC), Cryolife (CRY), Axonics Modulation Technologies (AXNX), Tactile Systems Technology (TCMD), Orthofix Medical (OFIX), Luminex (LMNX), Intersect ENT (XENT) and AngioDynamics (ANGO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Celgene (CELG), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), Broadcom (AVGO), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Mylan (MYL), Alibaba Group (BABA) and Bausch Health Companies (BHC).

Anika Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (11.30%), Kayne Anderson Rudnick Investment Management LLC (11.21%), BTIM Corp. (1.85%), THB Asset Management (1.45%), Capital Management Corp VA (0.79%) and California Public Employees Retirement System (0.59%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Joseph G Darling, Raymond J Land and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.

ANIK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Assenagon Asset Management S.A., THB Asset Management, Los Angeles Capital Management & Equity Research Inc., Gabelli Funds LLC, Systematic Financial Management LP and Prio Wealth Limited Partnership. View Insider Buying and Selling for Anika Therapeutics.

ANIK stock was purchased by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Kayne Anderson Rudnick Investment Management LLC, Bank of Montreal Can, Acadian Asset Management LLC, California Public Employees Retirement System, BTIM Corp., Capital Management Corp VA and Royce & Associates LP. View Insider Buying and Selling for Anika Therapeutics.

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ANIK stock can currently be purchased for approximately $40.48.

Anika Therapeutics has a market capitalization of $575.22 million and generates $105.56 million in revenue each year. The biotechnology company earns $18.72 million in net income (profit) each year or $1.84 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.View Additional Information About Anika Therapeutics.

The official website for Anika Therapeutics is http://www.anikatherapeutics.com/.

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]